Liability Related to the Sale of Future Royalties - Narrative (Details) - Royalty Pharma Agreement - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended | |||
|---|---|---|---|---|---|
Nov. 30, 2022 |
Jun. 30, 2024 |
Dec. 31, 2023 |
Jun. 30, 2026 |
Sep. 30, 2025 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
| Upfront payment received | $ 250.0 | ||||
| Milestone payment receivable | $ 160.0 | ||||
| Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial | 50.0 | ||||
| Milestone payment receivable upon FDA approval | 50.0 | ||||
| Milestone payment receivable upon receipt of royalty payments | 60.0 | ||||
| Royalty payment threshold | 70.0 | ||||
| Milestone payment received | $ 50.0 | ||||
| Future potential milestone payments payable | $ 110.0 | ||||
| Liability related to the sale of future royalties, interest rate | 9.00% | 8.30% | |||
| Maximum | |||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
| Initial transaction price | $ 410.0 | ||||